<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02505867</url>
  </required_header>
  <id_info>
    <org_study_id>2013H0228</org_study_id>
    <nct_id>NCT02505867</nct_id>
  </id_info>
  <brief_title>The Role of Sleep Disordered Breathing in Heart Failure Admissions</brief_title>
  <official_title>The Role of Sleep Disordered Breathing in Heart Failure Admissions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rami Khayat</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Philips Respironics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ohio State University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of in-hospital diagnosis and treatment of&#xD;
      sleep disordered breathing (SDB) on post-discharge mortality and readmissions in-&#xD;
      hospitalized patients with acute heart failure syndrome and reduced ejection fraction&#xD;
      (HFrEF).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the effect of in-hospital diagnosis and treatment of&#xD;
      sleep disordered breathing (SDB) on post-discharge mortality and readmissions in-&#xD;
      hospitalized patients with heart failure and reduced ejection fraction (HFrEF). The study is&#xD;
      a randomized controlled trial in HFrEF patients who are hospitalized with acute heart failure&#xD;
      syndrome (AHFS) and have an in-hospital sleep study diagnostic of SDB. Participants will be&#xD;
      randomized to either the current standard of care of AHFS treatment or an intervention arm in&#xD;
      which expedited treatment with adaptive servo ventilation is initiated immediately upon&#xD;
      in-hospital diagnosis of SDB.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    lack of funding&#xD;
  </why_stopped>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">December 1, 2016</completion_date>
  <primary_completion_date type="Actual">December 1, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hospital Readmissions</measure>
    <time_frame>Six Months</time_frame>
    <description>Number of participant hospital readmissions</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Sleep Apnea Syndromes</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Device - ASV Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants are provided with Adaptive Servo Ventilation (ASV) device during inpatient hospitalization or shortly after discharge.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No device provided</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Adaptive Servo Ventilation</intervention_name>
    <description>Participants are provided with an Adaptive Servo Ventilation (ASV) device for targeted treatment of SDB during inpatient hospitalization or shortly after discharge.</description>
    <arm_group_label>Device - ASV Therapy</arm_group_label>
    <other_name>Bipap AutoSV</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Admission diagnosis of heart failure and AHFS as defined by the following: A chief&#xD;
             complaint of dyspnea or fatigue; elevated left ventricular pressure. Elevated left&#xD;
             ventricular pressure is indicated by at least one of the following: signs of volume&#xD;
             overload pedal edema, crackles, consistent chest X-ray, increased measurement of left&#xD;
             ventricular end-diastolic diameter or volume, or elevated BNP level.&#xD;
&#xD;
          2. Previously unrecognized or recognized but untreated SDB diagnosed or confirmed on&#xD;
             attended inpatient sleep study during the index hospitalization with AHFS. SDB is&#xD;
             defined as one of the following syndromes:&#xD;
&#xD;
               1. AHI&gt;15 with more than 50% apneas being central (CSA); or&#xD;
&#xD;
               2. AHI&gt;30 events with more than 50% of the events being obstructive (severe OSA) in&#xD;
                  patients with LVEF &lt;30%.&#xD;
&#xD;
          3. Projected length of stay &gt;2 days on admission day to ensure uniformity of the&#xD;
             underlying severity of the AHFS and to enable the introduction of the ASV device and&#xD;
             education&#xD;
&#xD;
          4. LVEF &lt;45% within 1 year of admission. An echocardiogram may be performed to confirm&#xD;
             the LVEF during the hospitalization to determine eligibility.&#xD;
&#xD;
          5. Ongoing targeted treatment for heart failure during the current hospitalization&#xD;
             including at least one of the following: IV diuretics, IV infusion of inotropes or&#xD;
             vasodilators, or planned revascularization, or device therapy.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Patients who were on supplemental oxygen for an indication other than SDB or heart&#xD;
             failure prior to admission. These are patients who have chronic respiratory&#xD;
             insufficiency.&#xD;
&#xD;
          2. Patients on treatment targeting CSA or OSA (ASV, oxygen, or CPAP); and patients who&#xD;
             already provided and rejected positive airway pressure therapy due to intolerance of&#xD;
             the pressure or the claustrophobia.&#xD;
&#xD;
          3. Cardiogenic shock and hemodynamic instability with MAP less than 55 mmHg off&#xD;
             vasopressors, or concurrently on vasopressor treatment, left ventricular assist&#xD;
             devices, or intra-aortic Balloon Pump. Inotropic agents will not constitute an&#xD;
             exclusion criterion. Patients will be eligible once more stable off vasopressors.&#xD;
&#xD;
          4. Acute respiratory failure or insufficiency defined by (PaO2/FIO2) ratio less than 250,&#xD;
             or FIO2 requirement more than 40%. Patients are eligible to participate once their&#xD;
             FIO2 requirement is below 30%.&#xD;
&#xD;
          5. Overt neurological deficit or patients who arrived from a long-term care facility or&#xD;
             expected to be discharged to one; and patients who have very poor functional outcome&#xD;
             precluding ability to use the ASV device independently&#xD;
&#xD;
          6. Renal failure requiring renal replacement therapy; Patients will not be excluded if&#xD;
             they were undergoing ultra-filtration for volume removal.&#xD;
&#xD;
          7. Moderate to severe chronic obstructive lung disease (FEV1/FVC &lt; 55%).&#xD;
&#xD;
          8. Patients who are likely to receive heart transplant or left ventricular assist device&#xD;
             (LVAD) in the subsequent year. These are patients who have high standing on the&#xD;
             transplant list during the index hospitalization or have a cardiothoracic evaluation&#xD;
             for implantation of LVAD.&#xD;
&#xD;
          9. Patients on long term or &quot;bridging&quot; inotropic infusion, or short life expectancy due&#xD;
             to concomitant illness or heart failure&#xD;
&#xD;
         10. Patients who report severe sleepiness or who consider themselves at risk while&#xD;
             driving.&#xD;
&#xD;
         11. Patients who fail the secondary screening procedure. Secondary screening procedure&#xD;
             involves the patient being asked to wear the device and experience the pressure&#xD;
             delivery for at least 30 minutes while relaxed.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rami Khayat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Abraham, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>July 21, 2015</study_first_submitted>
  <study_first_submitted_qc>July 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2015</study_first_posted>
  <results_first_submitted>March 19, 2019</results_first_submitted>
  <results_first_submitted_qc>May 17, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 11, 2019</results_first_posted>
  <last_update_submitted>May 17, 2019</last_update_submitted>
  <last_update_submitted_qc>May 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University</investigator_affiliation>
    <investigator_full_name>Rami Khayat</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Device - ASV Therapy</title>
          <description>Participants are provided with Adaptive Servo Ventilation (ASV) device during inpatient hospitalization or shortly after discharge.&#xD;
Adaptive Servo Ventilation: Participants are provided with an Adaptive Servo Ventilation (ASV) device for targeted treatment of SDB during inpatient hospitalization or shortly after discharge.</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>No device provided</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Device - ASV Therapy</title>
          <description>Participants are provided with Adaptive Servo Ventilation (ASV) device during inpatient hospitalization or shortly after discharge.&#xD;
Adaptive Servo Ventilation: Participants are provided with an Adaptive Servo Ventilation (ASV) device for targeted treatment of SDB during inpatient hospitalization or shortly after discharge.</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>No device provided</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.33" lower_limit="29" upper_limit="66"/>
                    <measurement group_id="B2" value="46.33" lower_limit="31" upper_limit="72"/>
                    <measurement group_id="B3" value="46.83" lower_limit="29" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hospital Readmissions</title>
        <description>Number of participant hospital readmissions</description>
        <time_frame>Six Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Device - ASV Therapy</title>
            <description>Participants are provided with Adaptive Servo Ventilation (ASV) device during inpatient hospitalization or shortly after discharge.&#xD;
Adaptive Servo Ventilation: Participants are provided with an Adaptive Servo Ventilation (ASV) device for targeted treatment of SDB during inpatient hospitalization or shortly after discharge.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>No device provided</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Readmissions</title>
          <description>Number of participant hospital readmissions</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Device - ASV Therapy</title>
          <description>Participants are provided with Adaptive Servo Ventilation (ASV) device during inpatient hospitalization or shortly after discharge.&#xD;
Adaptive Servo Ventilation: Participants are provided with an Adaptive Servo Ventilation (ASV) device for targeted treatment of SDB during inpatient hospitalization or shortly after discharge.</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>No device provided</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Rami Khayat</name_or_title>
      <organization>The Ohio State Unveristy</organization>
      <phone>6142477717</phone>
      <email>rami.khayat@osumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

